A Predictive Model for Clinical Asthma Exacerbations Using Albuterol eMDPI (ProAir Digihaler): A 12-Week, Open-Label Study

被引：0
|
作者：
Safioti, G. [1 ]
Granovsky, L. [2 ]
Li, T. [3 ]
Reich, M. [2 ]
Cohen, S. [4 ]
Hadar, Y. [4 ]
Pleasants, R. [5 ]
Hill, T. [3 ]
DePietro, M. [3 ]
机构：
[1] Teva Pharmaceut, Amsterdam, Netherlands
[2] Teva Pharmaceut Ltd, Petah Tiqwa, Israel
[3] Teva Branded Pharmaceut R&D Inc, Malvern, PA USA
[4] Yellow Rd, Petah Tiqwa, Israel
[5] Univ N Carolina, Sch Med, Div Pulm Med & Crit Care, Chapel Hill, NC 27515 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2019年 / 199卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A7307
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Efficacy and tolerability of carbamazepine for the treatment of painful diabetic neuropathy in adults: a 12-week, open-label, multicenter study
    Saeed, Tariq
    Nasrullah, Muhammad
    Ghafoor, Adnan
    Shahid, Riaz
    Islam, Nadeem
    Khattak, Mohammad Usman
    Maheshwary, Neeta
    Siddiqi, Ahson
    Khan, Muhammad Athar
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2014, 7 : 339 - 343
  • [32] Lurasidone for the treatment of major depressive disorder with mixed features: results of a 12-week open-label extension study
    Stahl, S. M.
    Pikalov, A.
    Tocco, M.
    Mao, Y.
    Loebel, A.
    EUROPEAN PSYCHIATRY, 2019, 56 : S94 - S94
  • [33] A 12-week open-label, randomized, controlled trial and 24-week extension to assess the efficacy and safety of fluticasone propionate/formoterol in children with asthma
    Emeryk, Andrzej
    Klink, Rabih
    McIver, Tammy
    Dalvi, Prashant
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2016, 10 (04) : 324 - 337
  • [34] Preliminary results of an open-label, 12-week trial of adalimumab in the treatment of active ankylosing spondylitis
    Haibel, H
    Brandt, HC
    Rudwaleit, M
    Listing, J
    Braun, J
    Kupper, H
    Sieper, J
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 399 - 399
  • [35] Clinical evolution of substance use disorder patients during treatment with quetiapine: a 12-week, open-label, naturalistic trial
    Rizkallah, Elie
    Stip, Emmanuel
    Zhornitsky, Simon
    Pampoulova, Tania
    Gendron, Alain
    Rompre, Pierre-Paul
    Chiasson, Jean-Pierre
    Potvin, Stephane
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (18) : 2947 - 2951
  • [36] Imiquimod treatment of superficial and nodular basal cell carcinoma: 12-week open-label trial
    Peris, K
    Campione, E
    Micantonio, T
    Marulli, GC
    Fargnoli, MC
    Chimenti, S
    DERMATOLOGIC SURGERY, 2005, 31 (03) : 318 - 323
  • [37] Aripiprazole therapy in 20 older adults with bipolar disorder: A 12-week, open-label trial
    Sajatovic, Martha
    Coconcea, Nicoleta
    Ignacio, Rosalinda V.
    Blow, Frederic C.
    Hays, Robert W.
    Cassidy, Kristin A.
    Meyer, William J.
    JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (01) : 41 - 46
  • [38] Effects of bupropion on depression of Parkinson's disease: Open-label 12-week trial in Korea
    Kim, W. C.
    Kim, H. S.
    Oh, S. H.
    Kim, O. J.
    Lee, M. S.
    MOVEMENT DISORDERS, 2009, 24 : S241 - S241
  • [39] Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: A 12-week open-label, multicentre clinical trial
    Lublin, Henrik
    Haug, Hans-Joachim
    Koponen, Hannu
    Sigmundsson, Thordur
    Kolb, Stefan A.
    WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2009, 10 (04): : 710 - 718
  • [40] Comparison of Levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: A 2-week, multicenter, randomized, open-label study
    Donohue, James F.
    Hanania, Nicola A.
    Ciubotaru, Ronald L.
    Noe, Les
    Pasta, David J.
    Schaefer, Kendyl
    Claus, Raymond
    Andrews, William T.
    Roach, James
    CLINICAL THERAPEUTICS, 2008, 30 : 989 - 1002
12345